Why these ASX growth shares could rise 30%+

Analysts think these shares are undervalued. Let's see what they are saying.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you have a penchant for ASX growth shares like I do, then read on!

That's because the two in this article have not only been named as buys but have been tipped to rise at least 30% from current levels. Here's what analysts are saying about them:

A man sees some good news on his phone and gives a little cheer.

Image source: Getty Images

Life360 Inc (ASX: 360)

The team at Goldman Sachs thinks that this location technology company could be a quality ASX growth share to buy now.

It has a buy rating and $27.00 price target on its shares. This suggests that upside of 30% is possible for investors between now and this time next year.

The broker likes Life360 due to its huge total addressable market (TAM) and significant user monetisation opportunity. It explains:

We estimate Life360 is exposed to a US$12bn global TAM with a large opportunity to expand its product suite, grow average revenue per paying circle (ARPPC), increase payer conversion, and lift penetration rates outside of the US. The company has demonstrated its pricing power and is now exploring the latent monetisation opportunity of its >60mn user base via advertising.

Goldman also highlights that its shares are undervalued compared to peers. It adds:

 Life360's Subscription business currently trades at a discount to global subscription app peers when adjusting for its superior growth outlook. We see scope for re-rating as Life360 demonstrates operating leverage, ongoing subscription growth and user monetisation via ads. We are Buy rated on Life360.

Pro Medicus Limited (ASX: PME)

Bell Potter thinks that this health imaging technology company could be an ASX growth share to buy.

Its analysts have put a buy rating and $280.00 price target on its shares. Based on its current share price, this implies potential upside of 33% over the next 12 months.

Commenting on the company, the broker said:

Pro medicus is a leading health imaging IT provider. It's leading product is the Visage 7 Enterprise Viewer (the Visage Viewer). It is an essential component of a modern PACS with its main advantage being speed. Using this system the radiologist is able to view medical images from all major modalities at lightning fast speed including prior exams.

Visage 7 is the fastest, most versatile viewing software on the market and it is the key reason why Pro medicus has been successful in winning numerous high profile hospital contracts in the US, ahead of some of the largest global names in the industry.

Motley Fool contributor James Mickleboro has positions in Life360 and Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Life360. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

Person using a calculator with four piles of coins, each getting higher, with trees on them.
Growth Shares

Experts rate these 2 ASX growth shares as buys this month!

These businesses have plenty of positives according to analysts.

Read more »

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Growth Shares

3 ASX shares being unfairly punished by the market selloff and could rise 100%

Analysts think these shares could rebound strongly after heavy declines.

Read more »

Two players on a field pump their fists in the air, indicating two of the best
Growth Shares

2 amazing ASX shares to buy for long-term growth

Both billion dollar stocks combine strong growth, scalability and a leadership position.

Read more »

A beautiful woman holds up one finger with one hand and has her hand on her waist with the other as she smiles widely as though she is very pleased about something.
Growth Shares

2 ASX 200 shares that now have 60% upside: Analysts

With markets under pressure, some ASX 200 shares are starting to look more interesting. Here are two that stand out…

Read more »

Man looking amazed holding $50 Australian notes, representing ASX dividends.
Growth Shares

Where to invest $10,000 in ASX shares right now

These quality shares could be worth considering. Let's find out why.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Growth Shares

$3k to invest? 2 ASX shares to consider buying in 2026

These shares have been sold off and could offer major upside according to analysts.

Read more »

One girl leapfrogs over her friend's back.
Growth Shares

This dirt cheap ASX retail stock is tipped to double in value

Better execution and easing pressures could spark a powerful rebound.

Read more »

A smiling man points upwards with both fingers in an exaggerated sideways pose.
Growth Shares

Buy these 2 top ASX 200 shares and hold until 2036

Brokers are tipping 50 to 150% upside from here.

Read more »